WuXi Biologics (Cayman) Inc.
HKSE: 2269.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Zhisheng Chen
- Employees
- 12,575
- Headquarters
- Wuxi, China
- IPO year
- 2017
- Market cap
- HK$135.0B
- Website
- https://www.wuxibiologics.com
Loading 2269…
Loading profile data…Frequently asked questions about 2269
What does WuXi Biologics (Cayman) Inc. (2269.HK) do?
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contr...
Where does 2269.HK trade?
WuXi Biologics (Cayman) Inc. (2269.HK) trades on the Hong Kong Stock Exchange.
What sector is 2269.HK in?
WuXi Biologics (Cayman) Inc. (2269.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of WuXi Biologics (Cayman) Inc.?
Zhisheng Chen is the chief executive officer of WuXi Biologics (Cayman) Inc. (2269.HK).
Where is WuXi Biologics (Cayman) Inc. headquartered?
WuXi Biologics (Cayman) Inc. is headquartered in China.
Does 2269.HK pay a dividend?
WuXi Biologics (Cayman) Inc. (2269.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2269.HK go public?
WuXi Biologics (Cayman) Inc. (2269.HK) completed its initial public offering in 2017.